AUTHORS
Francesca Mauro, MD, PhD, Vittorio Bellomarino2, Andrea Visentin, MD,PhD3, Sara Pepe, MD, PhD4, Alessandro Sanna, MD5, Filomena Russo6, Annalisa Arcari, MD7, Riccardo Moia, MD, PhD8, Melania Celli9, Candida Vitale, MD, PhD10, Luca Laurenti Sr, MD11, Monica Tani12, Pietro Bulian13, Marika Porrazzo14, Paolo Sportoletti, MD, PhD15, Marzia Varettoni, MD16, Gian Matteo Rigolin, MD17, Pietro Rossi, MD18, Myriam Foglietta19, Roberto Marasca, MD20, Mariangela Di Trani21, Livio Trentin, MD22, Mariangela Iodice23, Valentina Arena24, Alfonso Piciocchi, MS25, Antonio Cuneo, MD26
AFFILIATIONS
1 Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy
2 Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy
3 Hematology unit, Department of Medicine, University of PadovaEmatologia, Azienda Ospedale - Università di Padova, Padova, Italy
4 Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy
5 Hematology Unit, Department of Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
6 Ematologia e Centro trapianti, AO Parma, Parma, Italy
7 Ospedale Guglielmo da Saliceto, Piacenza, Italy
8 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità di Novara, Novara, Italy
9 Ospedale Infermi, Rimini, Italy
10 Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy and University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy
11 Policlinico Universitario Agostino Gemelli, Rome, Italy
12 Ospedale Santa Maria delle Croci, Ravenna, Italy
13 IRCCS Centro di riferimento oncologico di Aviano, Aviano, Italy
14 AO Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
15 Centro di Ricerca Emato-Oncologica, Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy
16 UOC Ematologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo di Pavia, Pavia, Italy
17 Università degli Studi di Ferrara, Ferrara, Italy
18 Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico, IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori 'Dino Amadori', Meldola, Italy
19 SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
20 Hematology Unit, Department of Oncology and Hematology, Azienda Ospedaliero Universitaria of Modena, Policlinico Modena, Modena, Italy
21 Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy
22 Hematology unit, Department of Medicine, University of PadovaEmatologia, Azienda Ospedale - Università di Padova, Padova, Italy
23 GIMEMA Foundation, Rome, Italy
24 GIMEMA Foundation, Rome, Italy
25 GIMEMA Foundation, Rome, Italy
26 Università degli Studi di Ferrara, Ferrara, Italy
ABSTRACT
Front-line treatment strategies aimed at reducing residual disease have been shown to improve progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL), especially those with poor-prognosis genetic characteristics. The GIMEMA CLL2222-VIS study (NCT05478512) is an ongoing, prospective, phase 2, multicenter trial evaluating a minimal residual disease (MRD)-guided treatment strategy for previously untreated young patients (≤65 years) with high-risk CLL, defined by unmutated IGHV and/or TP53 disruption. Here, we present preliminary data from the first analysis of this trial.
The VIS study design includes an initial phase of 6 courses of the venetoclax-obinutuzumab (VenO) combination. At the end of the combination therapy (EOCT, month 9) with the VO regimen, minimal residual disease (MRD) was assessed by ASO-PCR in both peripheral blood (PB) and bone marrow (BM). Patients with undetectable MRD (uMRD) at <10-4 in PB and BM proceeded with 4 additional cycles of venetoclax alone (cycles 10-13), while those with detectable MRD (dMRD) at ≥10-4 received 12 cycles of the venetoclax and zanubrutinib (VZ) combination until the end of treatment (EOT; cycles 10-21) to enhance their response. Patients with persisting dMRD >10-6 continued treatment with zanubrutinib as a single agent until disease progression or severe toxicity.
In April 2025, to deepen responses at EOT and improve outcomes for this high-risk patient population, the uMRD threshold was lowered to <10-6, allowing treatment with the VZ combination for patients with dMRD ≥10-6. This study has two co-primary endpoints: 1. the rate of patients who achieve uMRD at EOCT with VO (month 9); 2. the rate of patients with dMRD at EOCT who achieve uMRD at EOT (month 21) with the VenZan combination.
As of March 12, 2026, 75 eligible patients have been enrolled in this study. The median age was 59 years (range, 29-65). 97% of patients were IGHV unmutated, and 3% were IGHV mutated with TP53 disruption (deletion and/or mutation). Advanced Rai stage III-IV was present in 33% of cases, B symptoms in 25%, and bulky nodes in 17%. The median follow-up in this study was 18.4 months (0.7-32 months). To date, 66 patients have completed the VO combination and undergone iwCLL response and MRD assessment. All evaluated patients responded, including 46 (70%) who achieved CR/CRi. Forty-four (67%) patients exhibited uMRD <10-4 in both PB and BM, including 20 (30%) with uMRD <10-6. Notably, in 3 of 4 patients with TP53 aberration who had MRD assessed at EOCT, uMRD <10-4 was observed. Per protocol, 4 additional cycles of venetoclax monotherapy were administered to 44 patients with uMRD <10-6, whereas 22 patients with dMRD ≥10-6 received 12 cycles of the VZ combination. MRD was assessed at EOT (cycle 21) in 11 of the 22 patients with dMRD >10-6 at cycle 9 who received 12 cycles of the VZ combination; 4 (36.4%) achieved uMRD in both PB and BM. Conversely, dMRD >10-6 was observed in 2 of 26 (8%) patients with uMRD at EOCT who received 4 additional cycles of V monotherapy. To date, no patients have died or progressed.
Adverse events were typical of those observed in patients receiving study drugs. Overall, grade ≥3 neutropenia/febrile neutropenia occurred in 16 (21%) patients, and grade ≥3 infection in 4 (5%) patients (pneumonia, 3; Legionella pneumonia, 1). Five (7%) patients experienced grade ≥3 infusion reactions to obinutuzumab, leading to discontinuation of obinutuzumab in 1 (1.3%). One (1.3%) patient discontinued treatment due to persistent diarrhea during venetoclax. Grade ≥3 hypertension was recorded in 4 (5%) patients (during venetoclax, 1; during venetoclax and zanubrutinib, 3).
In conclusion, preliminary data from this study indicate that the VO combination produced a high rate of deep responses, including uMRD, among patients with CLL and high-risk genetic features. This finding confirms the high efficacy of the front-line VO combination, as shown in the German CLL Study Group trials. Longer follow-up is needed to assess the second endpoint: whether adding zanubrutinib to venetoclax promotes clearance of residual leukemic cells in patients with dMRD at the EOCT. However, preliminary data are promising, showing early conversion from dMRD ≥10-6 to uMRD <10-6 in 4/11 patients on the VZ combination.
DISCLOSURES
Francesca Mauro, MD, PhD: BeOne - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Astrazeneca - Consultancy (Includes expert testimony)